Charles Goss

Washington University

$1,431,926

Attributed

$2,331,897

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.4M · FY2023–25

$2M$1.5M$1M$500K$0

'23

'24

'25

Funding mix

By agency

NIH$2,331,897 · 3

By mechanism

U19$1,131,936 · 1

R61$655,076 · 1

R33$544,885 · 1

Top collaborators

Most similar at Washington University

Same institution · by research overlap

Ramsey Hachem$6,763,198
J Evan Sadler$26,812,449
Andrew Eric Gelman$12,797,349
Deborah J Lenschow$10,764,209
Thalachallour Mohanakumar$18,846,664

Others in their field

Other Rising Stars on “Design”

Richard Smith · Medical Device Innovation Consortium$41,401,350
Jeffrey Leintz · National Opinion Research Center$38,969,238
Rhea Coler · Seattle Children'S Hospital$35,184,139
Julia Louise Moore Vogel · Scripps Research Institute, The$32,252,685
Christina Millin · Rho Federal Systems Division, Inc.$31,828,916
Sabrina Paganoni · Massachusetts General Hospital$30,895,527

Research focus

DesignLinkProspectiveCommunitiesPlayReportingCharacteristicsCessation Of LifeChronicAntibody TherapyAllograft RejectionAntithymoglobulinAdrenal Cortex HormonesB Cell DifferentiationAntibody-Mediated RejectionAllograftingCd4 Positive T LymphocytesCause Of DeathCd8-Positive T-LymphocytesCell CountCell Free DnaCell ProliferationCellsAntibody Formation

Grant awards (4)

A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection after Lung Transplantation$544,885

R33 · FY2025 · HL

Core B: Data Management$1,131,936

U19 · FY2024 · AI · contact PI

A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection after Lung Transplantation$283,671

R61 · FY2024 · HL

A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection after Lung Transplantation$371,405

R61 · FY2023 · HL